Supported by Karolinska Institute

The company is supported with grants from Karolinska Institute Innovation AB to promote business development.The company adopts a clear strategy developing Supernitro for the treatment of acute Pulmonary Hypertension. 

Funds for intensified development are provided through a convertible loan and soft money from the Novo Nordic Foundation, SweLife and Karolinska Innovation.